Research overview
Introduction
CAR-T cell therapy is now a central topic for haematology and oncology teams, but awareness does not automatically translate into clinical use. To understand where perception, experience and adoption intent diverge, SPER Market Research conducted an HCP perception study of CAR-T cell therapy among 50 specialists in the United States and Europe. This article sets out what they said about efficacy, safety, access and the future of the therapy.
What is an HCP perception study in CAR-T?
An HCP perception study is primary market research that measures healthcare professionals' awareness, clinical experience, attitudes and likely adoption of a therapy. This study assessed HCP awareness, clinical experience, perceptions of efficacy, safety concerns, treatment accessibility and future adoption potential of CAR-T cell therapy in oncology.
Study design: 50 HCPs, split evenly between the United States (25) and Europe (25). European respondents came from the UK, Germany, France, Italy and Spain, five per country. By specialty, respondents were haemato-oncologists (36%), haematologists (24%), medical oncologists (16%), cellular therapy specialists (16%) and paediatric oncologists (8%). Multiple-response percentages are calculated against N=50, so totals may exceed 100%. Findings are directional and should not be interpreted as statistically representative of the overall HCP population.
Key findings at a glance
| Key parameter | Finding |
|---|---|
| Moderate/high HCP familiarity | 76% |
| Positive clinical benefit perception | 64% |
| Leading indication: B-cell NHL | 84% |
| Key advantage: durable responses | 82% |
| Major safety concern: CRS | 88% |
| Access and infrastructure barriers | 76% |
| Clinical involvement | 72% |
| Potential adoption willingness | 68% |
How familiar are HCPs with CAR-T?
Seventy-six per cent of respondents are moderately (40%) or very (36%) familiar with CAR-T, while 24% report limited awareness. This reflects strong awareness among specialist oncology and haematology professionals.
Familiarity, however, is not the same as clinical experience. Twenty-four per cent prescribe or administer CAR-T, 22% manage patients after treatment and 26% refer eligible patients; 18% assess potential eligibility and 10% have no direct involvement. Seventy-two per cent report some form of clinical, patient management or referral involvement, which highlights the importance of distinguishing awareness from actual clinical experience.
How do specialists rate CAR-T clinical benefit?
Sixty-four per cent express positive perceptions of CAR-T's clinical benefit compared with available treatments for eligible relapsed/refractory patients (26% strongly agree, 38% agree). Twenty-two per cent are neutral and 14% disagree (10%) or strongly disagree (4%). Response durability, treatment line and patient eligibility remain important considerations.
The principal perceived advantages are:
Durable responses and targeted tumour-cell recognition stand out, particularly for patients with limited treatment alternatives.
Which cancers offer the greatest CAR-T potential?
Haematological malignancies remain the leading opportunity: B-cell non-Hodgkin lymphoma (84%), acute lymphoblastic leukaemia (74%), multiple myeloma (72%), chronic lymphocytic leukaemia (54%) and mantle cell lymphoma (52%). Solid tumours were selected by 34% and represent an emerging area requiring further clinical and technological advances.
What are the main safety concerns with CAR-T?
Cytokine release syndrome (CRS, 88%) and ICANS (84%) are the leading concerns. They are followed by:
Infection risk, prolonged cytopenias and long-term safety also influence treatment decisions.
Do cost, infrastructure and accessibility limit CAR-T adoption?
Yes, according to 76% of respondents (38% strongly agree, 38% agree); 16% are neutral and 8% disagree. In the US, insurance coverage and affordability are important considerations. In Europe, reimbursement, HTA decisions and uneven treatment centre availability influence access.
Will HCPs recommend or adopt CAR-T?
Sixty-eight per cent indicate willingness to recommend or adopt CAR-T for eligible patients: 32% would definitely and 36% would probably do so. Twenty per cent are undecided and 12% would probably (8%) or definitely (4%) not. Actual adoption remains dependent on eligibility, clinical outcomes, reimbursement and treatment infrastructure.
What will shape CAR-T over the next 5–10 years?
Respondents named the following as the developments with the greatest impact:
Future development will extend beyond indication expansion, with allogeneic platforms, in-vivo CAR-T, improved safety and manufacturing innovation emerging as important opportunities.
Frequently asked questions
What do physicians think of CAR-T cell therapy?
In this 50-HCP survey, 64% expressed positive perceptions of its clinical benefit, 76% were moderately or highly familiar with it, and 68% indicated willingness to recommend or adopt it.
What are the biggest safety concerns with CAR-T?
Cytokine release syndrome (88%) and ICANS (84%) lead, followed by infections and immune suppression (76%) and prolonged cytopenias (72%).
Which cancers do HCPs see as the best CAR-T opportunities?
B-cell non-Hodgkin lymphoma (84%), acute lymphoblastic leukaemia (74%) and multiple myeloma (72%).
What limits CAR-T adoption?
76% identified access-related barriers. In the US, insurance coverage and affordability; in Europe, reimbursement, HTA decisions and uneven treatment centre availability.
What developments will shape CAR-T next?
Expansion across indications and earlier lines (32%), improved safety and toxicity management (20%), allogeneic/off-the-shelf CAR-T (16%), solid tumours (14%) and in-vivo CAR-T (10%).
Can a 50-respondent survey represent all HCPs?
No. Findings are directional and should not be interpreted as statistically representative of the overall HCP population.
Conclusion
Specialists are familiar with CAR-T and largely positive about its clinical benefit, with durable responses the leading advantage. CRS and ICANS remain the dominant concerns, and 76% see cost, infrastructure and accessibility as barriers. With 68% willing to recommend or adopt it, adoption will depend on eligibility, clinical outcomes, reimbursement and treatment infrastructure. To explore HCP perception research for your therapy area, see SPER's primary intelligence services and KOL Atlas.



















